_256_384.jpg)
News | March 01, 2024
Suven announces merger of Cohance Lifesciences
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Both the Ministries signed MoU for anaemia control among adolescent girls using Ayurveda interventions
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
Comprehensive clinical development programs being initiated for each investigational candidate
Innovent will supply sintilimab for the collaborated clinical trial
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Subscribe To Our Newsletter & Stay Updated
